Loading...

Hurel Corporation - Clarinex©: The Hunt for the Unproducible Metabolite

420 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Mar 17, 2014

A Hurel© video case study: Clarinex©: The Hunt for the Unproducible Metabolite

The Importance of Full Correct Prediction of Human Metabolites in Discovery and Preclinical Development

"Clarinex®: The Hunt for the Unproducible Metabolite" a Hurel Corporation video white paper presented by Ronald E. White, Ph.D. Formerly Vice President of Drug Metabolism at the Schering-Plough Research Institute, Dr. White was directly engaged in the pre-clinical development of desloratadine (Clarinex®), the second-generation drug that Schering developed to follow its blockbuster medication, loratadine (Claritin®). Dr. White's case study traces the research challenges Schering faced in attempting to answer the FDA's questions about 3-hydroxy desloratadine, a circulating metabolite which in vitro models then available to Schering were unable to generate but which the HµRELhumanTM model was shown to produce successfully. It also comments on how a correctly predictive in vitro tool like Hurel might have effected the economics of the commercial launch of Clarinex®. The video runs about four minutes.

Loading...

to add this to Watch Later

Add to

Loading playlists...